Welcome to our dedicated page for CTS SEC filings (Ticker: CTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CTS Corporation (NYSE: CTS) SEC filings page aggregates the company’s regulatory disclosures, including the Form 8-K current reports cited in its public communications. These filings provide structured information on topics such as quarterly financial results, material definitive agreements, leadership changes, and board composition, giving investors a detailed view of how CTS reports key events and obligations.
CTS uses Form 8-K to furnish earnings press releases that summarize net sales, net earnings, margins, cash flow, and guidance ranges for annual sales and adjusted diluted earnings per share. These filings often include or reference investor presentations used in meetings with investors and analysts. The company also explains its use of non-GAAP financial measures alongside U.S. GAAP metrics and describes the categories of adjustments it applies, such as restructuring charges, environmental charges, acquisition-related adjustments, foreign exchange items, non-cash pension items, and certain discrete tax items.
Other CTS filings document material definitive agreements, such as the five-year unsecured revolving credit facility described in a Form 8-K. That filing outlines the size of the revolving credit facility, swing line and letter of credit sublimits, alternative currency sublimit, leverage and interest coverage covenants, and the replacement of a prior unsecured credit facility. Additional 8-K reports cover the appointment or resignation of senior officers, the election of new directors, committee assignments, and related compensation or indemnification arrangements.
On Stock Titan, CTS filings are updated as they become available from EDGAR, and AI-powered summaries can help explain the key points of lengthy documents. Investors can use this page to review CTS’s current reports on operations and financial condition, governance changes, and financing arrangements, as well as to understand how the company frames forward-looking statements and risk factors by referencing its Annual Report on Form 10-K and other filings.
CTS Corporation expanded its Board of Directors from seven to eight members and elected Kimberly MacKay to fill the new seat, effective November 5, 2025. MacKay serves as SVP, General Counsel and Corporate Secretary of West Pharmaceutical Services and will join CTS’s Nominating, Governance and Sustainability Committee and Technology and Transactions Committee.
As a non-employee director, she will receive compensation consistent with other non-employee directors as described in the Company’s March 28, 2025 proxy statement. The Company reported no arrangements leading to her selection and no related person transactions requiring disclosure under Item 404(a). CTS will enter into its standard indemnification agreement with her, and a related press release was furnished as Exhibit 99.1 on November 6, 2025.
CTS Corporation (NYSE: CTS) reported Q3 2025 results. Net sales were $142.97M, up from $132.38M a year ago, driven by Industrial ($37.10M vs $30.75M), Medical ($21.96M vs $18.02M), and Aerospace & Defense ($25.36M vs $20.59M), while Transportation softened ($58.55M vs $63.03M). Operating earnings were essentially flat at $20.94M. Net earnings were $13.69M vs $18.08M, with diluted EPS of $0.46 vs $0.59 as higher SG&A and R&D offset gross profit gains.
Year to date, sales reached $404.05M vs $388.30M and net earnings were $45.58M vs $43.91M (diluted EPS $1.52 vs $1.43). Cash provided by operations was $72.89M, ending cash was $110.30M, and long‑term debt was $90.70M (weighted average rate 5.56%). The company repurchased 399,500 shares for $16.74M in Q3 and $40.08M year to date, with approximately $21.34M remaining under its program. Remediation reserves increased to $15.90M; for the Asheville, NC matter, the company recorded a $5.97M loss estimate within an updated exposure range of $5.97M to $8.29M. Shares outstanding were 29,052,423 as of October 21, 2025.
CTS Corporation furnished an investor presentation under Item 7.01 (Regulation FD) in a Form 8‑K. The presentation, included as Exhibit 99.1 and dated October 2025, may be used in meetings with investors and analysts during the fiscal year ended December 31, 2025. The company states the materials are furnished, not filed, and are not subject to Section 18 liability or incorporated by reference unless specifically referenced.
CTS Corporation furnished an update on its business by providing a press release with certain results for the third quarter ended September 30, 2025, and related presentation materials. The company also announced a live webcast on October 28, 2025 to discuss these results.
The materials are furnished under Items 2.02 and 7.01 and are not deemed filed under the Exchange Act. Attached exhibits include the earnings release (Exhibit 99.1), the Q3 2025 slide deck (Exhibit 99.2), and the cover page interactive data file (Exhibit 104).
BlackRock, Inc. filed Amendment No. 5 to Schedule 13G reporting beneficial ownership of CTS CORP common stock. BlackRock reports 4,334,951 shares beneficially owned, representing 14.7% of the class as of the event date 09/30/2025.
BlackRock has sole voting power over 4,265,805 shares and sole dispositive power over 4,334,951 shares, with no shared voting or dispositive power. The filing states the securities are held in the ordinary course and not for the purpose of changing or influencing control. The filing also notes that iShares Core S&P Small-Cap ETF has an interest of more than five percent of CTS CORP’s outstanding common stock.
EARNEST Partners, LLC reports beneficial ownership of 1,976,058 shares of CTS Corp common stock, representing 6.7% of the class as of the reported event. The filing shows EARNEST holds sole dispositive power over all 1,976,058 shares and sole voting power over 1,337,689 shares, with shared voting power for 188,130 shares. The firm is filing as an investment adviser and states that no single client account holds more than 5% of the class. The filing includes a certification that the shares were acquired in the ordinary course of business and are not intended to influence control of the issuer.
CTS Corporation (CTS) filed a Form 4 showing that Chief Legal & Administrative Officer Mark R. Pacioni received 4,600 restricted stock units (RSUs) on 07/29/2025. The award is coded “A” (grant) and carries a cash price of $0, indicating it is part of routine equity compensation rather than an open-market purchase. According to the footnote, the RSUs vest one-third annually. After the grant, Pacioni’s direct beneficial ownership totals 4,600 CTS common shares; no derivative securities were reported. The transaction is small relative to CTS’s share count and does not signal any change in strategic outlook or provide new financial information. Overall, this is a standard insider equity award with negligible impact on the company’s capital structure or valuation.
CTS Corporation filed a Form 8-K dated 24 July 2025 under Item 7.01 (Reg FD). The filing furnishes, but does not file, an investor presentation (Exhibit 99.1) that may be used in meetings with investors and analysts during fiscal-year 2025. Management explicitly disclaims that the furnished material should be deemed “filed” for Exchange Act liability or incorporated by reference into other SEC filings. No financial results, transaction details, or strategic announcements are included. Exhibit 104 covers the Inline XBRL cover-page data.